12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Custirsen sodium: Phase III started

OncoGenex began the open-label, international Phase III ENSPIRIT trial to compare weekly 640 mg IV custirsen plus 75 mg/m 2 IV Taxotere docetaxel given on day 1 of a 21-day cycle vs. Taxotere alone in about 1,100 NSCLC patients who have progressed after first-line platinum-based chemotherapy. Patients will receive 3 loading doses of custirsen 5-9...

Read the full 265 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >